Vyloy Alternatives Compared
Vyloy (zolbetuximab) | Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
---|
Vyloy (zolbetuximab) | Ogivri (trastuzumab) | Taxotere (docetaxel) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Gastric Cancer. Vyloy may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Breast Cancer - Adjuvant, Esophageal Carcinoma, Breast Cancer, Gastric Cancer. Ogivri may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Prostate Cancer, Breast Cancer, Gastric Cancer, Breast Cancer - Metastatic, Non Small Cell Lung Cancer, Head and Neck Cancer. Taxotere may also be used for purposes not listed in this... View more |
Related suggestions Gastric Cancer
|
|||||||||||||||
More about Vyloy (zolbetuximab) | More about Ogivri (trastuzumab) | More about Taxotere (docetaxel) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
Taxotere has an average rating of 5.2 out of 10 from a total of 11 ratings on Drugs.com. 36% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||
View all Vyloy side effects |
View all Ogivri side effects |
View all Taxotere side effects |
||||||||||||||||
Drug Class | ||||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
View all Vyloy prices |
View all Ogivri prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||||||||||
Dosage Forms | ||||||||||||||||||
|
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
Other trastuzumab brands include: Herceptin, Hercessi, Herzuma, Kanjinti, Ontruzant, Trazimera | Other docetaxel brands include: Docivyx | ||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||
984 hours |
924 hours |
11.1 hours |
||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 143 drugs are known to interact with Vyloy:
|
A total of 191 drugs are known to interact with Ogivri:
|
A total of 520 drugs are known to interact with Taxotere:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
October 18, 2024 |
December 01, 2017 |
May 14, 1996 |
||||||||||||||||
WADA Class View classifications | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient Resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.